NCT00593151View on ClinicalTrials.gov

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

March 31, 2009

Conditions
Hepatitis C
Interventions
OTHER

Locteron (controlled-release interferon alpha 2b)

biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection

BIOLOGICAL

pegylated IFNa2b

biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg

Trial Locations (5)

22003

Inova Center for Liver Diseases, Annandale

23249

McGuire DVAMC, McGuire Research Institute, Richmond

48202

Henry Ford Hospital, Detroit

75208

Methodist Dallas Medical Center, Dallas

78215

Alamo Medical Research, San Antonio

Sponsors
All Listed Sponsors
lead

Biolex Therapeutics, Inc.

INDUSTRY